S636
Clinical – Head & neck
ESTRO 2026
swallowing/chewing’ were used to assess mucositis, xerostomia, and dysphagia, respectively. Missing PROs were imputed by linear interpolation with rule-based boundary handling to preserve temporal structure. A multi-symptom burden score was defined as the mean of the three items. For each patient, the area under the symptom-time curve was computed using the trapezoidal rule, and the time-weighted mean (tw_mean) score was derived to summarise overall symptom burden. Differences across TGFB1 genotypes (C/C, C/T, T/T) were evaluated using Kruskal- Wallis and Wilcoxon rank-sum tests with Benjamini- Hochberg correction. Results: Among 165 genotyped patients (C/C 46%, C/T 43%, T/T 11%), 114 had at least two PRO timepoints available. The T allele represented the minor allele (MAF = 0.32, 95% CI 0.26–0.38). Mucositis showed an acute pattern, peaking during RT and resolving shortly after treatment (Figure 1). Xerostomia and dysphagia persisted for several months post-RT before gradually declining. In the late post-treatment phase ( ≥ 2 months), dysphagia scores remained highest among C/C carriers, while T/T homozygotes exhibited a steeper recovery. However, no statistically significant differences in tw_mean scores were observed between genotype groups for any side effect (Figure 2).
Ren J, Eriksen JG, Nijkamp JA, and Korreman S, ”Comparing different CT, PET and MRI multi-modality image combinations for deep learning-based head and neck tumor segmentation”, Acta Oncol 60(11):1399- 1406, doi: 10.1080/0284186X.2021.1949034, 2021. [3] Rasmussen ME, Vestergaard CD, Kallehauge JF, …, and Korreman S, ”RadDeploy: A framework for integrating in-house developed models seamlessly into radiotherapy workflows”, Phys Imag Rad Oncol 31:100607, doi: 10.1016/j.phro.2024.100607, 2024. Keywords: Target segmentation, artificial intelligence, Longitudinal analysis of patient-reported symptom trajectories by TGFB1 genotype in head and neck cancer radiotherapy Laia Humbert-Vidan 1 , Lina Shbita 2 , Samuel L. Mulder 2 , Lucas B. McCullum 2 , Ashley R. Harrington 2 , Sergi Benavente Norza 1 , Raquel Granado 1 , Goretti Mallorquí Fernandez 1 , Amy C. Moreno 2 , Katherine A. Hutcheson 3 , Stephen Y. Lai 3 , Sara Gutiérrez-Enríquez 4 , Xavier Maldonado Pijoan 1 , G. Brandon Gunn 2 , Clifton D. Fuller 2 1 Radiation Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. 2 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 3 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA. 4 Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain Digital Poster Highlight 3782 Purpose/Objective: Radiotherapy (RT) is curative for many head and neck cancer (HNC) patients but often induces normal-tissue side effects that compromise function and quality of life. These adverse events share dysregulated fibrotic mechanisms driven by transforming growth factor- β (TGF- β ), a mediator of fibroblast activation, extracellular matrix deposition, and chronic inflammation. As genetic variants in TGFB1 may influence susceptibility to radiation-induced effects, the objective of this study was to investigate genotype- symptom associations to improve normal tissue complication probability modelling and personalised RT strategies. Material/Methods: Peripheral blood samples from patients with HNC treated with curative-intent RT at MD Anderson Cancer Center were genotyped for the rs1800469 TGFB1 variant. Patient-reported outcomes (PROs) were collected using the MD Anderson Symptom Inventory- Head and Neck questionnaire at baseline, weekly during RT, and up to 60 months post-RT. The items ‘mouth/throat sores’, ‘dry mouth’, and ‘difficulty
Made with FlippingBook - Share PDF online